French pharmaceutical firm Sanofi has entered into collaboration with the life sciences team at Google to improve care and outcomes for people with type one and type two diabetes.
Both the parties will jointly work to collect, analyse and understand information impacting diabetes as well as work on new digital technology and tools for enhancing the management and treatment of this disease.
The deal will combine Sanofi’s expertise in diabetes treatments and devices with Google’s skill in analytics, miniaturised electronics and low power chip design.
According to the International Diabetes Federation (IDF), diabetes is expected to affect 592 million people across the world by 2035.
The companies intend to use data and miniaturised technology to provide patients with more tools to self-manage their disease as well as offer healthcare professionals with the ability to better support and treat patients.
Sanofi CEO Olivier Brandicourt said: "This initiative combines Sanofi’s strength and knowledge in diabetes with Google’s leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care."
As part of the deal, the companies will develop new tools that bring together many of the previously siloed pieces of diabetes management and allow new kinds of interventions.
The deal will see development of health indicators such as blood glucose and haemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.
Google life sciences team CEO Andy Conrad said: "With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes.
"Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life."